Enabling CGP from Liquid Biopsy with TruSight Oncology 500 ctDNA v2

3 November 2023

TruSight™ Oncology 500 ctDNA v2 is now available! Our next version comprehensive genomic profiling (CGP) from liquid biopsy (blood) offers higher analytical sensitivity from lower cfDNA input, faster turn-around time from purified nucleic acid to insights and a more streamlined workflow with automation options coming in 2024! Hear about these new features from Illumina development team and the excitement from early access users at Frederick National Laboratory. The information and opinions expressed herein are that of the Frederick National Laboratory for Cancer Research (FNLCR) and not the United States Government, National Institutes of Health or the National Cancer Institute. The FNLCR is a Federally Funded Research and Development Center sponsored by the National Cancer Institute and operated by Leidos Biomedical Research, Inc. Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: https://www.facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illu... Instagram: https://www.instagram.com/illuminainc/ Twitter: https://twitter.com/illumina #liquidbiopsy #precisionmedicine #CGP #NGS #oncology

Share this article on